This study included 6994 patients diagnosed between 2013 and 2015 with clinical T1/T2, clinical N0 HER2+ breast cancer treated with NAC, and HER2-targeted therapy followed by surgical resection (Table 1). This evidence concerns the gene ERBB2 and breast carcinoma.